Table 2.
Univariate and Multivariate Analyses of Factors Associated with OS in Combined Training and Testing Cohorts
| Factors | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% Cl | P-value | HR | 95% Cl | P-value | |
| Age: years | 1.025 | 1.005–1.046 | 0.012 | |||
| Sex: male vs female | 0.910 | 0.536–1.545 | 0.727 | |||
| Tumor Size: cm | 1.111 | 1.066–1.157 | <0.001 | |||
| Tumor Number: Single vs Multiple | 0.599 | 0.406–0.884 | 0.01 | |||
| Serum AFP, μg/L | 1.001 | 1.000–1.001 | <0.001 | 1.000 | 1.000–1.001 | 0.031 |
| Serum CEA, μg/L | 1.062 | 1.027–1.098 | <0.001 | |||
| Serum CA 19–9, U/mL | 1.005 | 1.000–1.011 | 0.066 | |||
| Serum TBIL, μmol/L | 1.007 | 0.997–1.016 | 0.188 | |||
| Serum ALB, g/L | 0.962 | 0.923–1.004 | 0.076 | |||
| Serum ALT, U/L | 1.000 | 0.997–1.002 | 0.776 | |||
| Serum AST, U/L | 1.000 | 0.997–1.002 | 0.928 | |||
| Serum GGT, U/L | 1.003 | 1.002–1.004 | <0.001 | |||
| Serum ALP, U/L | 1.008 | 1.004–1.011 | <0.001 | |||
| Serum PLT, ×109/L | 0.996 | 0.993–1.000 | 0.028 | |||
| Serum PT, S | 1.217 | 1.061–1.395 | 0.005 | |||
| Serum Cre, μmol/L | 1.005 | 0.998–1.012 | 0.192 | |||
| Micro-vascular invasion: no vs yes | 0.662 | 0.454–0.965 | 0.032 | 1.613 | 1.006–2.585 | 0.047 |
| Laennec Score | 1.763 | 1.401–2.218 | <0.001 | |||
| TNM: I vs II vs III vs IV | 1.656 | 1.360–2.016 | <0.001 | 1.540 | 1.201–1.975 | 0.001 |
| New Cirrhosis Score | 1.079 | 1.062–1.095 | <0.001 | 1.072 | 1.054–1.090 | <0.001 |
Notes: TNM, cancer tumor-node-metastasis classification system; statistically significant values are bold.
Abbreviations: OS, overall survival; Cl, confidence interval; AFP, preoperative level of serum α-fetoprotein; CEA, preoperative level of serum carcinoembryonic antigen; CA19-9, preoperative level of serum cancer antigen 19-9.